Radiotherapy, Intensity-Modulated: Clinical Trials

594 trials of Radiotherapy, Intensity-Modulated, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

217 completed, 98 unknown, 82 active not recruiting, 79 recruiting. 289 Phase 2, 130 Phase 1, 111 Phase 3, 87 Not applicable, 7 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2289Completed 107, Unknown 52, Active not recruiting 40, Terminated 33, Recruiting 32, Not yet recruiting 13, Withdrawn 9, Suspended 2, Enrolling by invitation 1
Phase 1130Completed 65, Terminated 23, Active not recruiting 14, Recruiting 10, Unknown 9, Withdrawn 5, Suspended 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 3111Recruiting 23, Unknown 23, Completed 22, Active not recruiting 21, Not yet recruiting 12, Terminated 5, Withdrawn 3, Suspended 2
Not applicable87Completed 29, Terminated 16, Unknown 14, Recruiting 13, Active not recruiting 9, Withdrawn 5, Not yet recruiting 1
Early Phase 17Completed 3, Recruiting 2, Active not recruiting 1, Unknown 1
Phase 43Unknown 2, Completed 1

Follow Radiotherapy, Intensity-Modulated: new trials by email Literature Review of Radiotherapy, Intensity-Modulated trials Research Report on Radiotherapy, Intensity-Modulated

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Chemotherapy, Computed Tomography, Endoscopic Procedure - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Not applicableNot yet recruitingCity of Hope Medical Center302027-06-222026-11-09
Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical Cancer
Biospecimen Collection, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Phase 3Not yet recruitingNRG Oncology5502027-05-192026-11-10
Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma
Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection - Grade 1 Meningioma, Grade 2 Meningioma
Phase 3Not yet recruitingNRG Oncology4642027-01-282026-08-25
NG101m Adjuvant Therapy in Glioblastoma Patients
Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme
Phase 1 / Phase 2Not yet recruitingNeuGATE Theranostics522027-01-012025-10-21
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Phase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)3742026-12-042026-11-18
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities
Phase 3RecruitingSWOG Cancer Research Network2962026-12-022026-10-13
IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma
Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT) - Diffuse Intrinsic Pontine Gliomas (DIPG)
Phase 3Not yet recruitingShandong Cancer Hospital and Institute1422026-12-012026-10-09
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Phase 3Not yet recruitingOhio State University Comprehensive Cancer Center2282026-12-012026-09-16
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Phase 2Not yet recruitingSun Yat-sen University2982026-12-012026-10-27
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC)
Phase 2Not yet recruitingSun Yat-sen University2142026-12-012026-10-29
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
Advanced radiotherapy techniques - Malignant Tumor, Benign Neoplasm
Not yet recruitingIRCCS San Raffaele100002026-11-152026-10-29
Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer
Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab - Head and Neck Cancer
Phase 2Not yet recruitingKevin Contrera1402026-11-152026-11-12
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2Not yet recruitingMayo Clinic502026-11-012026-11-09
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma
Phase 2RecruitingAlliance for Clinical Trials in Oncology1642026-10-142026-11-03
Role of Postoperative Radiotherapy in T1-T2N0M0 Glottic Carcinoma Involving the Anterior Commissure
intensity modulated radiotherapy (IMRT) - Early Stage Glottic Squamous Cell Carcinoma Involving the Anterior Commissure
Not applicableRecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine382026-09-162026-08-24
Role of Radiotherapy in T1-T2N0M0 Glottic Carcinoma With Poor Differentiation
Radiation: intensity modulated radiotherapy (IMRT) - Early Stage Glottic Squamous Cell Carcinoma With Poor Differentiation
Not applicableRecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine382026-09-162026-08-24
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC)
Phase 3RecruitingFirst Affiliated Hospital of Guangxi Medical University2662026-09-082026-11-09
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2) - HPV-unrelated Head and Neck Squamous Cell Carcinoma
Phase 2Not yet recruitingFudan University1042026-09-012026-08-20
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease
Phase 3Not yet recruitingUniversity College, London822026-09-012026-10-01
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8
Phase 1 / Phase 2RecruitingUniversity of Washington122026-08-202026-08-25

Showing 20 of 594. Sign in to see all of them.

Conditions studied

Squamous Cell Carcinoma of Head and Neck (82)  ·  Head and Neck Neoplasms (75)  ·  Nasopharyngeal Carcinoma (62)  ·  Prostatic Neoplasms (51)  ·  Oropharyngeal Neoplasms (30)  ·  Carcinoma, Non-Small-Cell Lung (27)  ·  Carcinoma, Squamous Cell (24)  ·  Breast Neoplasms (23)  ·  Rectal Neoplasms (23)  ·  Glioblastoma (22)  ·  Carcinoma (18)  ·  Uterine Cervical Neoplasms (18)  ·  Brain Neoplasms (16)  ·  Neoplasm Metastasis (16)  ·  Nasopharyngeal Neoplasms (15)

Sponsors

Sun Yat-sen University (45)  ·  National Cancer Institute (NCI) (36)  ·  Radiation Therapy Oncology Group (21)  ·  NRG Oncology (18)  ·  M.D. Anderson Cancer Center (17)  ·  City of Hope Medical Center (16)  ·  Memorial Sloan Kettering Cancer Center (16)  ·  Mayo Clinic (11)  ·  University of Texas Southwestern Medical Center (10)  ·  Washington University School of Medicine (10)  ·  Chinese Academy of Medical Sciences (9)  ·  Fudan University (9)  ·  UNC Lineberger Comprehensive Cancer Center (8)  ·  AHS Cancer Control Alberta (7)  ·  University of Washington (7)

Countries

United States (327)  ·  China (130)  ·  Canada (71)  ·  France (18)  ·  Belgium (12)  ·  Italy (12)  ·  Switzerland (12)  ·  Australia (10)  ·  India (10)  ·  Israel (10)  ·  United Kingdom (10)  ·  Hong Kong (9)  ·  South Korea (9)  ·  Germany (8)  ·  Japan (8)

Top investigators

Jun Ma, M.D. (6)  ·  Douglas Adkins, M.D. (3)  ·  Fang-Yun Xie, M.D. (3)  ·  Guopei Luo, MD (3)  ·  Guopei Zhu, M.D. (3)  ·  Ming-Yuan Chen, MD,PhD (3)  ·  Robert Haddad, MD (3)  ·  Rufus Scrimger, MD (3)  ·  Steven H Lin (3)  ·  Wei Jiang, Ph.D. (3)  ·  Wilson Roa, MD (3)  ·  Anna Pawlowska (2)  ·  Anuja Jhingran, MD (2)  ·  Chong Zhao, MD PhD (2)

Results publications

PMID 25057165, PMID 27840089, PMID 31150573, PMID 36884035, PMID 36990609, PMID 16467544, PMID 22543211, PMID 27044935, PMID 28267695, PMID 28356973, PMID 28837405, PMID 29584545, PMID 30207593, PMID 32017652, PMID 35355438, PMID 37751207, PMID 38050737, PMID 41343184, PMID 10974628, PMID 11208820, PMID 11448365, PMID 11704310, PMID 12007937, PMID 12117328, PMID 12128137, PMID 12838028, PMID 14645636, PMID 14759776, PMID 14801776, PMID 14967461, PMID 15142632, PMID 15183474, PMID 15800321, PMID 1584260, PMID 16425991, PMID 16515704, PMID 17234359, PMID 17706308, PMID 17825932, PMID 17848281, PMID 17960013, PMID 18285602, PMID 18374511, PMID 18786783, PMID 18855050, PMID 19056184, PMID 19342953, PMID 19363712, PMID 19405086, PMID 19564532

NIH funding

U10CA180868 (34), U10CA021661 (12), P30CA033572 (9), U10CA180820 (9), P30CA013330 (5), P30CA015083 (4), U10CA180886 (4), P30CA015704 (3), P30CA016059 (3), P30CA072720 (3), P30CA138292 (3), U10CA027469 (3), U10CA098543 (3), U19CA021239 (3), UG1CA189867 (3)